Quasiglaucoma (Normal-Tension Glaucoma) - Symptoms, Causes, Treatment & Prevention

```html

Overview

Quasiglaucoma, more commonly called Normal‑Tension Glaucoma (NTG), is a type of open‑angle glaucoma in which optic‑nerve damage and visual‑field loss occur despite intra‑ocular pressure (IOP) that stays within the statistically normal range (typically ≤ 21 mm Hg). Because IOP is not elevated, NTG can be more challenging to recognize and may be mistaken for age‑related vision changes.

• Who it affects: Adults over 40 years, with a peak incidence in the sixth and seventh decades. Women are slightly more likely than men.
• Population prevalence: NTG accounts for 30–50 % of all primary open‑angle glaucoma cases worldwide. In Asian populations, the proportion can exceed 70 % (see Mackey et al., 2014).
• Geographic pattern: Higher rates are reported in Japan, Korea, and other East‑Asian countries, suggesting genetic and vascular components.

Even though the pressure is “normal,” the optic nerve remains vulnerable, often due to compromised blood flow, connective‑tissue abnormalities, or subtle structural weaknesses.

Symptoms

NTG typically progresses slowly and may be asymptomatic until moderate visual loss occurs. Below is a complete symptom list with brief explanations:

• Peripheral (side) vision loss: Gradual narrowing of the visual field, often first noticed when navigating in dim light or when missing objects at the edges of sight.
• Blind spots (scotomas): Small dark areas that may appear in the central or peripheral vision.
• Difficulty with contrast: Trouble distinguishing objects that have similar colors or shades, especially under low‑light conditions.
• Glare and halos: Increased sensitivity to bright lights, such as oncoming headlights.
• Frequent changes in prescription glasses: Vision may deteriorate faster than expected for age‑related presbyopia.
• Eye discomfort or mild pain: Rare, but some patients report a vague eye ache or pressure sensation.
• No pain or redness: Unlike acute angle‑closure glaucoma, NTG rarely produces acute eye pain, redness, or sudden vision loss.

Causes and Risk Factors

While the exact cause of NTG remains under investigation, several mechanisms and risk factors have been identified:

Pathophysiologic mechanisms

• Vascular dysregulation: Impaired blood flow to the optic nerve head (ischemia) due to systemic hypotension, nocturnal dipping, or vasospasm.
• Structural susceptibility: Thinner lamina cribrosa or weaker connective tissue may make the optic nerve more vulnerable to normal pressure levels.
• Genetic predisposition: Variants in the OPTN (optineurin) and TBK1 genes have been linked to NTG in familial studies.
• Autoimmune or inflammatory factors: Some research suggests low‑grade inflammation may contribute to optic‑nerve injury.

Key risk factors

• Age: Risk doubles every decade after age 40.
• Family history: First‑degree relatives with any type of glaucoma increase risk 2–3 fold.
• Low systemic blood pressure: Especially nocturnal hypotension (blood pressure < 90 mm Hg while sleeping) has been associated with faster progression.
• Vasospastic disorders: Migraine, Raynaud’s phenomenon, or systemic hypertension treated aggressively.
• Myopia (nearsightedness): High myopia (> 6 D) is linked with greater NTG prevalence.
• Ethnicity: Asian and Japanese ancestry show higher rates.
• Thin central corneal thickness (CCT): May mask true IOP and is an independent risk factor.

Diagnosis

Diagnosing NTG involves a combination of clinical examination, imaging, and functional testing to demonstrate optic‑nerve damage despite normal IOP.

1. Comprehensive eye exam

• Visual‑acuity testing.
• Refraction to assess refractive error.
• Slit‑lamp examination of the anterior segment.

2. Intra‑ocular pressure measurement

• Goldmann applanation tonometry (gold standard).
• Multiple readings over different times of day to rule out diurnal spikes.

3. Optic‑nerve assessment

• Dilated fundus exam: Looks for characteristic cupping, neuroretinal rim thinning, or disc hemorrhages.
• Optical coherence tomography (OCT): Quantifies retinal nerve‑fiber layer (RNFL) thickness and ganglion‑cell complex loss.

4. Visual‑field testing

• Standard automated perimetry (Humphrey 24‑2 or 30‑2) to map scotomas.
• Progression analysis over months to years.

5. Additional investigations (when indicated)

• Blood‑pressure monitoring, especially nocturnal ambulatory readings.
• Fundus fluorescein angiography or OCT‑angiography to evaluate ocular perfusion.
• Genetic testing (research‑only) for known NTG‑associated mutations.

Diagnosis is confirmed when:

1. IOP ≤ 21 mm Hg on at least three separate visits,
2. Typical glaucomatous optic‑nerve changes are present, and
3. Corresponding visual‑field defects are documented.

Treatment Options

Because optic‑nerve damage is pressure‑related even at “normal” levels, the primary goal is to lower IOP further—usually by 20–30 % from baseline—while addressing vascular and lifestyle contributors.

1. Medications

• Prostaglandin analogues (e.g., latanoprost, bimatoprost): First‑line; increase uveoscleral outflow, can lower IOP by 25–30 %.
• Beta‑blockers (e.g., timolol, betaxolol): Reduce aqueous production; useful as adjuncts.
• Alpha‑agonists (e.g., brimonidine): Dual action—decrease production and increase outflow.
• Carbonic anhydrase inhibitors (e.g., dorzolamide, oral acetazolamide): Effective for patients needing additional pressure reduction.
• Rho‑kinase inhibitors (e.g., netarsudil): Newer class that improves outflow; may have additional neuroprotective benefits.

Adherence is crucial; missing doses can accelerate progression. Discuss side‑effects (e.g., prostaglandin‑induced iris darkening) with patients.

2. Laser and surgical procedures

• Selective laser trabeculoplasty (SLT): Targets pigment cells in the trabecular meshwork, enhancing outflow. Often used when medications are insufficient or not tolerated.
• Minimally invasive glaucoma surgery (MIGS): Devices such as the iStent® or Hydrus® micro‑stent gently increase outflow with a low complication profile.
• Traditional filtering surgery (trabeculectomy or tube shunt): Reserved for advanced disease or when IOP cannot be lowered adequately with less invasive means.

3. Vascular‑targeted strategies

• Blood‑pressure optimization: Avoid excessive nocturnal dips; consider adjusting antihypertensive timing.
<.
• **Low‑dose calcium‑channel blockers:** May improve ocular blood flow in vasospastic patients (evidence limited).
• Systemic antioxidants & diet: Diets rich in omega‑3 fatty acids, flavonoids, and leafy greens may support microvascular health (observational data).

4. Lifestyle modifications

• Regular aerobic exercise (≥ 150 min/week) improves ocular perfusion.
• Quit smoking; nicotine causes vasoconstriction.
• Limit caffeine intake if it triggers blood‑pressure spikes.
• Use protective eyewear to avoid ocular trauma.

Living with Quasiglaucoma (Normal‑Tension Glaucoma)

Managing NTG is a lifelong commitment. Below are practical tips to help patients maintain vision and quality of life.

Daily eye‑care routine

• Instill eye drops exactly as prescribed—use a 5‑minute interval between different drops.
• Keep a medication calendar or smartphone reminder.
• Store drops at room temperature and discard after the expiration date.

Monitoring and follow‑up

• Schedule comprehensive eye exams every 3–6 months, or as directed by your ophthalmologist.
• Track visual‑field changes using home‑based screening tools (e.g., Amsler grid) and report new blind spots promptly.
• Maintain a log of blood‑pressure readings, especially nighttime values.

Adapting daily activities

• Improve home lighting—bright, even illumination reduces reliance on peripheral vision.
• Use contrast‑enhancing tools such as bold‑type fonts, high‑contrast keyboards, or yellow‑tinted lenses for glare.
• When driving, avoid night travel if peripheral vision is compromised; consider a driver‑assessment program.

Emotional well‑being

• Join support groups (online or local) to share experiences.
• Consider counseling if anxiety about vision loss interferes with daily life.
• Stay active—physical fitness is linked to slower glaucoma progression.

Prevention

Because NTG cannot be completely prevented, the focus is on reducing modifiable risk factors:

• Control systemic blood pressure: Aim for a target that avoids both hypertension and excessive hypotension (usually 120/80 mm Hg daytime, with nocturnal dip < 10 %).
• Maintain a healthy weight and exercise regularly.
• Limit alcohol and avoid illicit drugs that can cause vasoconstriction.
• Regular eye examinations: Early detection is the most effective preventive strategy.
• Manage comorbidities: Diabetes, hyperlipidemia, and sleep apnea should be optimally treated.

Complications

If NTG progresses unchecked, several serious outcomes can occur:

• Advanced visual‑field loss: Leads to tunnel vision and eventual blindness.
• Falls and injuries: Peripheral vision loss increases risk of tripping or misjudging obstacles.
• Reduced independence: Affecting driving ability, reading, and occupational tasks.
• Psychological impact: Depression, anxiety, and social isolation are documented in chronic glaucoma patients.

When to Seek Emergency Care

References

• Mackey, S. et al. “Normal‑Tension Glaucoma: An Overview of Epidemiology and Pathogenesis.” Ophthalmology Review, 2014. PMCID: PMC3898165
• American Academy of Ophthalmology. “Primary Open‑Angle Glaucoma Preferred Practice Pattern.” 2023. AAO PPP
• Mayo Clinic. “Normal‑pressure glaucoma.” Updated 2022. Mayo Clinic
• World Health Organization. “Global Initiative for the Elimination of Avoidable Blindness.” 2021. WHO
• Cleveland Clinic. “Glaucoma – Types, Symptoms, Diagnosis, and Treatment.” 2023. Cleveland Clinic
• National Eye Institute (NEI). “Normal‑Tone Glaucoma Fact Sheet.” 2022. NEI

```